Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07594392 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE

StatusRecruiting
PhaseNot specified
Started2026-09-21
View on ClinicalTrials.gov ↗

Amendment history

2026-09-03
notable
Study Status v4
Recruitment opened
Trial started: 2026-09-21 (last estimated 2026-10)
Start date2026-08→2026-10
2026-08-24
minor
Study Identification, Study Status v3
Re-verified, no change to tracked fields
2026-07-14
minor
Study Identification, Study Status, Sponsor/Collaborators v2
Start date2026-06→2026-08
Collaborators+31 characters
National Cancer Institute (NCI)
2026-05-19
minor
Study Status, Study Design, Arms and Interventions, Eligibility, IPDSharing v1
Eligibility criteria+12 characters
[...] inum chemotherapy, neck radiation exposure of at least 1000 centigray (cGy), or chest radiation exposure of at least 1000 cGy (with pot [...]
2026-05-12
minor
Original filing
Childhood cancer survivors are at increased risk for premature atherosclerotic cardiovascular disease (ASCVD) due to cancer treatment-related exposures, including radiation therapy and platinum-based chemotherapy. Current ASCVD risk assessment tools may underestimate cardiovascular risk in younger survivors. This observational study performs detailed cardiovascular phenotyping using imaging, blood-based biomarkers, and vascular function testing among adult survivors enrolled in the St. Jude Lifetime Cohort (SJLIFE), with comparison to community controls, to better characterize subclinical ASCVD risk and inform survivor-specific prevention strategies. Primary Objective: Perform deeper phenotyping of SJLIFE participants at treatment-related risk of atherosclerotic cardiovascular disease \[ASCVD\] to facilitate early detection of pathophysiological targets appropriate for remediation. Secondary Objectives: Determine the distribution of lipoprotein (a) levels and prevalence of elevated levels among survivors with any treatment related exposure-based risk for ASCVD overall and then compared to community controls. Evaluate prevalence of clinical and imaging markers of ASCVD risk among survivors exposed only to platinum chemotherapy and compare that to community controls.
Trial Details
NCT Number NCT07594392
Lead Sponsor St. Jude Children's Research Hospital
Collaborators: National Cancer Institute (NCI)
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 650 participants
Start Date 2026-09-21
Primary Completion 2030-06 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-24